参考文献/References:
[1] Baranowska-Kortylewicz J, Dalrymple GV, Harrison KA, et al. On the safety 5-[125I]iodo-2-deoxy-uridine preclinical evaluation in swine[J]. Acta Oncol, 1996, 35(7):925-933.
[2] Taverna P, Hwang HS, Schupp JE, et al. Inhibition of base excision repair potentiates iododeoxyuridine-induced eytotoxicity and radiosensitization[J]. Cancer Res, 2003, 63(4):838-846.
[3] Yan T, Seo Y, Schupp JE, et al. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther, 2006, 5(4):893-902.
[4] Dupertuis YM, Xiao WH, De Tribolet N, et al. Unlabeled iododeoxyuridine increase the rate of uptake of[125] iododeoxyuridine in human xenografted glioblastomas[J]. Eur J Nucl Med Mol Imaging, 2002, 29(4):499-505.
[5] Howell RW, Bishayee A. Bystander effects caused by nonuniform distributions of DNA-incorporated(125)I[J]. Micron, 2002, 33(2):127-132.
[6] Xue LY, Butler NJ, Makrigiorgos GM, et al. Bystander effect produced by radiolabeled tumor cells in vivo[J]. Proc Nat Acad Sci USA, 2002, 99(21):13765-13770.
[7] Kassis AI, Wen PY, Van den Abbeele AD, et al. 5-[125I]iodo-2-deoxyuridine in the of brain radiotherapy tumors in rats[J]. J Nucl Med, 1998, 39(7):1148-1154.
[8] Kassis AI, Dahman BA, Adalstein SJ. In vivo therapy of neoplastic meningitis with methotrexate and 5-[125I]iodo-2-deoxyuridine[J]. Acta Oncol, 2000, 39(6):731-737.
[9] Galanis E, Goldberg R, Reid J, et al. Phase Ⅰ trial of sequential administration of raltitrexed(Tomudex) and 5-iodo-2’-deoxyuridine (IdUrd)[J]. Ann Oncol, 2001, 12(5):701-707.
[10] Dupertuis YM, Vazquez M, Mach JP, et al. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine[J]. Cancer Res, 2001, 61(21):7971-7977.
[11] Seo Y, Yan T, Schupp JE, et al. The interaction between two radiosensitizers:5-iododeoxyuridine and caffeine[J]. Cancer Res, 2006, 66(1):490-498.
[12] 马晓东,Dillehay LE,Williams JR,et al.局部缓释125I-UdR治疗恶性星形细胞瘤实验研究[J].中华神经外科疾病研究杂志,2005,4(4):293-298.
[13] Malrs RJ, Wideman CL, Angerson WJ, et al. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model[J]. Br J Cancer, 2000, 82(1):74-80.
[14] Kinsella TJ, Vielhuber KA, Kunugi KA, et al. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2’-deoxyribose as a prodrug for 5-iodo-2’-deoxyufidine radiosensitization in U251 human glioblastoma xenografts[J]. Clin Cancer Res, 2000, 6(4):1468-1475.
[15] Harrington K J, Syrigos KN, Uster PS, et al. Targeted radiosensitisation by pegylated liposome-encapsulated 3’, 5’-O-dipalmitoyl 5-iodo-2’-deoxyuridine in a head and neck cancer xneograft model[J]. Br J Cancer, 2004, 91(2):366-373.
[16] Semnani ES, Wang K, Adelstein SJ, et al. 5-[123I/125I]iodo-2-deoxyuridine in metastatic lung cancer:radiopharmaceutical formulation affects targeting[J]. J Nucl Med, 2005, 46(5):800-806.
[17] Chiou RK, Dalrymple GV, Baranowska-Kortylewicz J, et al. Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer[J]. J Urology, 1999, 162(1):58-62.
[18] Macapinlac HA, Kemeny N, Daghighian F, et al. Pilot clinical trial of 5-[125I]iodo-2’-deoxyuridine in the treatment of colorectal cancer metastatic to the liver[J]. J Nucl Med, 1996, 37(4 suppl):25s-29s.
[19] Ou XH, Kuang AR, Peng X, et al. Study on the possibility of insulin as a carrier of IUdR for hepatocellular carcinoma-targeted therapy[J]. World J Gastroenterol, 2003, 9(8):1675-1678.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[5]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[6]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[7]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]